Amit M Oza

Amit M Oza, BSc, MD, MBBS, FRCPC

Dr. Amit Oza is a Senior Staff Physician and Professor of Medicine at the Princess Margaret Cancer Centre and the University of Toronto. He is cross-appointed to the Department of Obstetrics and Gynecology at the University of Toronto. He graduated from St. Bartholomew's Hospital, University of London (UK), in 1983 and completed his internal medicine and medical oncology training in UK. He completed Clinical Research Fellowships at St. Bartholomew's Hospital/Imperial Cancer Research Fund, London (UK), Princess Margaret Hospital, Toronto and at the Netherlands Cancer Institute, Amsterdam. His postgraduate research thesis was on Molecular Epidemiology of Hodgkin's Disease. He is a Fellow of the Royal College of Physicians of London and Canada.

Dr. Oza has been the principal investigator and co-investigator in phase I, II, and III trials for gynecological cancer and advanced colorectal malignancies. His research interests are focused towards the development, assessment and validation of novel therapeutic strategies for cancer including molecular targeted therapies. Many of these studies also incorporate novel endpoints and translational research which is developed in close relationship with scientists and pathologists from the OCI/PMH.

Dr. Oza has been the recipient of various awards such as the University of Toronto Award for Teaching Excellence for the Medical Oncology Training Program, the Hasselback Award for Teaching Excellence from Princess Margaret Hospital and many others. He has also been principal and co-author of numerous publications in major peer reviewed journals such as Cancer Research, Journal of Clinical Oncology, Annals of Oncology, Investigational New Drugs and Clinical Cancer Research.

He is currently interim Head, Department of Medical Oncology & Hematology, Co-Director of the Robert and Maggie Bras and Family Drug Development Program at the Princess Margaret Cancer Centre. This is the largest new drug development program in Canada and the only center outside the US to have a contract with the NIH for Early Phase Therapeutic studies. He is Co-Chair for the Gynecological Cancer Steering Committee of the National Cancer Institute and represents the Princess Margaret Phase II Consortium at the Gynecologic Cancer InterGroup.

Am Soc Clin Oncol Educ Book. 2016;35:e247-57
Fujiwara K, McAlpine JN, Lheureux S, Matsumura N, Oza AM
Front Oncol. 2016;6:119
Karakasis K, Burnier JV, Bowering V, Oza AM, Lheureux S
J Transl Med. 2016;14(1):83
Goss GD, Jonker DJ, Laurie SA, Weberpals JI, Oza AM, Spaans JN, la Porte C, Dimitroulakos J
Invest New Drugs. 2016 Mar 21;
Kummar S, Wade JL, Oza AM, Sullivan D, Chen AP, Gandara DR, Ji J, Kinders RJ, Wang L, Allen D, Coyne GO, Steinberg SM, Doroshow JH
Curr Oncol Rep. 2016 Apr;18(4):23
Rodriguez-Freixinos V, Karakasis K, Oza AM
Expert Opin Pharmacother. 2016 Feb 26;
Rodriguez-Freixinos V, Mackay HJ, Karakasis K, Oza AM
Genet Med. 2015 Nov 12;
Abou Tayoun AN, Al Turki SH, Oza AM, Bowser MJ, Hernandez AL, Funke BH, Rehm HL, Amr SS
Br J Cancer. 2015 Nov 10;
Lheureux S, Oza AM, Laurie SA, Halford R, Jonker D, Chen E, Keller D, Bourade V, Wang L, Doyle L, Siu LL, Goel R
Int J Radiat Oncol Biol Phys. 2015 Sep 18;
Milosevic MF, Townsley CA, Chaudary N, Clarke B, Pintilie M, Fan S, Glicksman R, Haider M, Kim S, MacKay H, Yeung I, Hill RP, Fyles A, Oza AM

Pages


 

Co-director, Robert and Maggie Bras and Family Drug Development Program​
Professor, Department of Medicine, University of Toronto
Head, Department of Medical Oncology & Hematology